ADVERTORIAL FEATURE Baillie G
Disrupting disease with artificial intelligence
The value of your investment and any income from it can go down as well as up and as a result your capital may be at risk .
In half of coronary artery disease cases , the presenting symptom is death . That ’ s why early detection matters . NHS doctors in England now have a new diagnostic weapon to fight the disease . Used in the US since 2014 , HeartFlow Analysis uses artificial intelligence ( AI ) to turn a CT scan of the patient ’ s heart into an interactive , 3D model . With its help , cardiologists can assess
potential problems with the arterial blood supply and decide on treatment . Not only does the Californian company ’ s program work but , according to the UK ’ s National Institute for Health & Care Excellence ( NICE ), it represents a £ 391 per patient cost saving to the NHS . Thus , it satisfies the rule of thumb used by Tom Slater , joint manager of the Scottish Mortgage Investment Trust , for medtech , biotech and other healthcare companies considered for the trust ’ s £ 19bn portfolio : “ Does this company improve patient outcomes ? Does it reduce the costs of the system ?” At present , about 17 per cent of Scottish Mortgage is invested in medically-related firms , compared with 12 per cent five years ago and 3 per cent 10 years ago . The trust ’ s
/ 20 /